IHS Chemical Week

Regions :: Western Europe :: Switzerland

Lonza to Expand Cytotoxic API Capacity in Switzerland

12:51 AM MDT | May 12, 2011 | Deepti Ramesh

Lonza says it will invest SF24 million ($27 million) to expand cytotoxic manufacturing capabilities at the company’s site at Visp, Switzerland. Cytotoxic active pharmaceutical ingredients (APIs) are widely used in oncology therapeutics, one of the fastest growing segments of the pharma and biotech industries, Lonza says. “This investment speeds our efforts to establish the Lonza Visp site as a center of excellence for high potency manufacturing,” says Stefan Stoffel, head of Lonza’s chemical manufacturing business unit. “With the...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2012 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa